Daily Hong Kong Stock Market News Briefing (February 26, Wednesday)

USHK News
2025.02.26 01:18

  1. Shimao Group (00813.HK) announced on the Hong Kong Stock Exchange that the company is pleased to announce that, with mutual consent, the High Court has issued an order to withdraw the petition against the company.

  2. Baidu Group (09888.HK): Entered into an agreement with JOYY to acquire the mainland China video entertainment live streaming business (i.e., YY Live). Baidu has paid a total acquisition price of approximately USD 2.1 billion.

  3. CSPC Pharmaceutical Group (01093.HK): Expects a year-on-year decrease of approximately 26% in net profit for 2024. This is mainly due to the price reductions of approximately 58% and 23% for its two major products, Jinyouli and Duomeisu, in the "3+N" alliance centralized procurement in the Beijing-Tianjin-Hebei region.

  4. China Everbright Water (01857.HK): Expects revenue of approximately HKD 6.852 billion for 2024, a slight year-on-year increase of 2%; net profit is expected to be approximately HKD 1.02 billion, a year-on-year decrease of 14%.

  5. BUD APAC (01876.HK) announced its 2024 results, with profit attributable to equity holders of USD 726 million, a year-on-year decrease of 14.79%, and a final dividend of 5.66 cents per share.

  6. CHINA LIT (00772.HK) issued a profit warning, expecting an annual net loss of approximately HKD 150 million to HKD 250 million, turning from profit to loss year-on-year.

  7. ASMPT (00522.HK) announced its 2024 results, with profit attributable to shareholders of HKD 345 million, a year-on-year decrease of 51.74%.

  8. Hansoh Pharmaceutical (03692.HK): Its self-developed B7-H3 targeted antibody-drug conjugate (ADC) injection HS-20093 has been approved by the National Medical Products Administration (NMPA) of China for inclusion in breakthrough therapy drugs

Source: USHK News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.